|
MechanismNLGase stimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
Phase 0 biomarker assessment of day-to-day, within-day and interindividual variability in GBA pathway biomarkers in healthy adults and patients with Parkinson*s disease with and without heterozygous GBA1-mutations - GCase variability in GBA mutation
A NON-RANDOMIZED, OPEN-LABEL, CROSS-OVER, DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECTS OF BIA 28-6156 AT STEADY-STATE ON THE PHARMACOKINETICS OF LEVODOPA/CARBIDOPA AND LEVODOPA/BENSERAZIDE IN HEALTHY SUBJECTS. - BIA 28-6156 & L-Dopa plus Carbidopa or Benserazide DDI in healthy subjects
100 Clinical Results associated with Bial R&d Investments SA
0 Patents (Medical) associated with Bial R&d Investments SA
100 Deals associated with Bial R&d Investments SA
100 Translational Medicine associated with Bial R&d Investments SA